INVEGA HAFYERA paliperidone (as palmitate) 700 mg in 3.5 mL modified release suspension for injection pre-filled syringe Australien - engelska - Department of Health (Therapeutic Goods Administration)

invega hafyera paliperidone (as palmitate) 700 mg in 3.5 ml modified release suspension for injection pre-filled syringe

janssen-cilag pty ltd - paliperidone palmitate, quantity: 1092 mg - injection, suspension - excipient ingredients: polysorbate 20; macrogol 4000; citric acid monohydrate; monobasic sodium phosphate monohydrate; sodium hydroxide; water for injections - invega hafyera, a 6-month injection, is indicated for the maintenance treatment of schizophrenia in adult patients who have been adequately treated with the 1-month paliperidone palmitate injectable product for at least four months or the 3-month paliperidone palmitate injectable product following at least one 3-month injection cycle.

TREVICTA Israel - engelska - Ministry of Health

trevicta

j-c health care ltd - paliperidone as palmitate - extended release suspension for injection - paliperidone as palmitate 200 mg / 1 ml - paliperidone - trevicta, a 3 monthly injection, is indicated for the maintenance treatment of schizophrenia in adult patients who are clinically stable on 1 monthly paliperidone palmitate injectable product

XEPLION 50 MG Israel - engelska - Ministry of Health

xeplion 50 mg

j-c health care ltd - paliperidone as palmitate - suspension for injection extended release - paliperidone as palmitate 100 mg / 1 ml - paliperidone - paliperidone - xeplion is indicated for the acute and maintenance treatment of schizophrenia in adults.xeplion is indicated for the treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and antidepressants

PALIPERIDONE TEVA 150 MG Israel - engelska - Ministry of Health

paliperidone teva 150 mg

teva israel ltd - paliperidone as palmitate - suspension for injection extended release - paliperidone as palmitate 100 mg / 1 ml - paliperidone - paliperidone teva® is indicated for the acute and maintenance treatment of schizophrenia in adults.paliperidone teva® is indicated for the treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and antidepressants.

PALIPERIDONE TEVA 25 MG Israel - engelska - Ministry of Health

paliperidone teva 25 mg

teva israel ltd - paliperidone as palmitate - suspension for injection extended release - paliperidone as palmitate 100 mg / 1 ml - paliperidone - paliperidone teva® is indicated for the acute and maintenance treatment of schizophrenia in adults.paliperidone teva® is indicated for the treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and antidepressants.

PALIPERIDONE TEVA 75 MG Israel - engelska - Ministry of Health

paliperidone teva 75 mg

teva israel ltd - paliperidone as palmitate - suspension for injection extended release - paliperidone as palmitate 100 mg / 1 ml - paliperidone - paliperidone teva® is indicated for the acute and maintenance treatment of schizophrenia in adults.paliperidone teva® is indicated for the treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers and antidepressants.

PALIPERIDONE- paliperidone tablet, extended release USA - engelska - NLM (National Library of Medicine)

paliperidone- paliperidone tablet, extended release

remedyrepack inc. - paliperidone (unii: 838f01t721) (paliperidone - unii:838f01t721) - paliperidone 9 mg - paliperidone extended-release tablets are indicated for the treatment of schizophrenia [see clinical studies (14.1)] . the efficacy of paliperidone extended-release tablets in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents, as well as one maintenance trial in adults. paliperidone extended-release tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers and/or antidepressant therapy [see clinical studies (14.2)] . the efficacy of paliperidone extended-release tablets in schizoaffective disorder was established in two 6-week trials in adults. paliperidone extended-release tablets are contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in the paliperidone extended-release tablets formulation. hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with risperidone and

PALIPERIDONE tablet, film coated, extended release USA - engelska - NLM (National Library of Medicine)

paliperidone tablet, film coated, extended release

mylan institutional inc. - paliperidone (unii: 838f01t721) (paliperidone - unii:838f01t721) - paliperidone 3 mg - paliperidone extended-release tablets are indicated for the treatment of schizophrenia [see clinical studies (14.1)] . the efficacy of paliperidone extended-release tablets in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents, as well as one maintenance trial in adults. paliperidone extended-release tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers and/or antidepressant therapy [see clinical studies (14.2)] . the efficacy of paliperidone extended-release tablets in schizoaffective disorder was established in two 6-week trials in adults. paliperidone extended-release tablets are contraindicated in patients with a

PALIPERIDONE tablet, film coated, extended release USA - engelska - NLM (National Library of Medicine)

paliperidone tablet, film coated, extended release

mylan pharmaceuticals inc. - paliperidone (unii: 838f01t721) (paliperidone - unii:838f01t721) - paliperidone 1.5 mg - paliperidone extended-release tablets are indicated for the treatment of schizophrenia [see clinical studies (14.1)] . the efficacy of paliperidone extended-release tablets in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents, as well as one maintenance trial in adults. paliperidone extended-release tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers and/or antidepressant therapy [see clinical studies (14.2)] . the efficacy of paliperidone extended-release tablets in schizoaffective disorder was established in two 6-week trials in adults. paliperidone extended-release tablets are contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in the paliperidone extended-release tablets formulation. hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with risperidone and in

PALIPERIDONE tablet, extended release USA - engelska - NLM (National Library of Medicine)

paliperidone tablet, extended release

patriot pharmaceuticals, llc - paliperidone (unii: 838f01t721) (paliperidone - unii:838f01t721) - paliperidone 3 mg - paliperidone extended-release tablets are indicated for the treatment of schizophrenia [see clinical studies (14.1)] . the efficacy of paliperidone extended-release tablets in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents, as well as one maintenance trial in adults. paliperidone extended-release tablets are indicated for the treatment of schizoaffective disorder as monotherapy and an adjunct to mood stabilizers and/or antidepressant therapy [see clinical studies (14.2)] . the efficacy of paliperidone extended-release tablets in schizoaffective disorder was established in two 6-week trials in adults. paliperidone extended-release tablets are contraindicated in patients with a known hypersensitivity to either paliperidone or risperidone, or to any of the excipients in the paliperidone extended-release tablets formulation. hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients t